Evidence map›Paper›PMID 31010865›Full record

ArticleAntimicrobial agents and chemotherapy2019

Efficacy of Aerosolized Rifaximin versus Tobramycin for Treatment of Pseudomonas aeruginosa Pneumonia in Mice.

Brandon D Kirby, Roy Al Ahmar, T Ryan Withers, Meagan E Valentine, Monica Valentovic, Timothy E Long, James R Gaskins, Hongwei D Yu

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Rifaximin potentiates clarithromycin againstJAC-antimicrobial resistance · 2023
    Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Brandon D KirbyDepartment of Biomedical Sciences, Joan C. Edwards School of Medicine at Marshall University, Huntington, West Virginia, USA.
Roy Al AhmarDepartment of Biomedical Sciences, Joan C. Edwards School of Medicine at Marshall University, Huntington, West Virginia, USA.
T Ryan WithersProgenesis Technologies, LLC, Robert C. Byrd Biotechnology Science Center, Huntington, West Virginia, USA.
Meagan E ValentineProgenesis Technologies, LLC, Robert C. Byrd Biotechnology Science Center, Huntington, West Virginia, USA.
Monica ValentovicDepartment of Biomedical Sciences, Joan C. Edwards School of Medicine at Marshall University, Huntington, West Virginia, USA.
Timothy E LongDepartment of Pharmaceutical Science and Research, School of Pharmacy, Marshall University, Huntington, West Virginia, USA.
James R GaskinsMicrobiology Department, Cabell Huntington Hospital, Huntington, West Virginia, USA.
Hongwei D YuDepartment of Biomedical Sciences, Joan C. Edwards School of Medicine at Marshall University, Huntington, West Virginia, USA yuh@marshall.edu.ORCID 0000-0002-8546-0158
Marshall University · USCabell Huntington Hospital · US

Funding

WV INBRE: The Inhibitor of Growth Family Member 4 (ING4) inhibits L-Type Amino Acid Transporter 1 (LAT1) expression to suppress Breast CancerP20GM103434 · NIGMS · MARSHALL UNIVERSITY · PI Travis Salisbury · 2012 to 2026
$61.1M
Bioengineering a non-pathogenic bacteria to produce medically-relevant biopolymersR44GM113545 · NIGMS · PROGENESIS TECHNOLOGIES, LLC · PI NILES, RICHARD M. · 2017 to 2018
$1.1M
NIGMS NIH HHS P20 GM103434NIGMS NIH HHS R44 GM113545
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AlginatesAmikacinAnimalsAnti-Bacterial AgentsBiofilmsCystic FibrosisDisease Models, AnimalFemaleLungMaleMiceMice, Inbred C57BLMice, Inbred DBAMicrobial Sensitivity TestsPneumoniaPseudomonas aeruginosaAlginatesAmikacinAnti-Bacterial AgentsRifaximinTobramycinalginateantibiofilmsantimicrobial activitymouse pneumoniamultidrug resistancenebulizationPseudomonas aeruginosarifaximintobramycin

Identifiers

PMID31010865
PMCPMC6591630
OpenAlexW2951913665

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.